Study of 18FET PET in functional pituitary adenomas with indeterminate MRI findings
Key facts
- Phase
- Phase 2
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorTrial details
- Who runs it
- Centre Hospitalier Universitaire De Lille
- Trial code
- EU 2025-523829-17-00
- Record updated
- 2 July 2026
- Original description
Estimate the positivity rate using 18FET PET in patients with de novo, recurrent, or persistent functional AP who are eligible for adenoma-targeted treatment (surgery and/or external beam radiation therapy) and have non-contributory pituitary MRIRead full original descriptionShow less
18F-fluoro-ethyl-tyrosine (18FET) PET for difficult clinical situations in functional pituitary adenoma. A prospective, single arm, single center study. (FET-PIT)
Estimate the positivity rate using 18FET PET in patients with de novo, recurrent, or persistent functional AP who are eligible for adenoma-targeted treatment (surgery and/or external beam radiation therapy) and have non-contributory pituitary MRI
Inclusion: Male and/or female; Aged 18 years or older; Suspected functional pituitary adenoma (prolactinoma, Cushing's disease, acromegaly, thyrotropic adenoma), de novo or recurrence/persistence; With indeterminate pituitary MRI; Patient covered by social security; Patient willing to comply with all study procedures and duration; Patient eligible for surgery and/or radiotherapy in case of positive 18FET PET scan.
Exclusion: Known hypersensitivity to radiopharmaceuticals; Patients suffering from liver disease or severe uncontrolled epilepsy; Pregnancy; Administrative reasons: inability to receive informed consent, inability to participate in the entire study, lack of social security coverage, refusal to sign the consent form; Patient with active alcohol consumption; Patients deprived of their liberty (guardianship, curatorship, etc.); Patients who do not speak French.